J Headache Pain 24(1):89
Additionally, studies on youth and adolescent use of GLP-1s, another rapidly growing area of interest, are now possible with this real-world data
Patients who benefit most are typically adults with a BMI over 27, with or without conditions such as insulin resistance or metabolic syndrome
Cavet ME, Harrington KL, Vollmer TR, Ward KW, Zhang JZ
Clinical trials, including Phase 1 and Phase 2, have demonstrated Retatrutides substantial efficacy in weight reduction, with participants losing up to 24.2% of their starting body weight over 48 weeks, alongside improvements in glycemic control and lipid profiles
Depending on the nutrition profile, meal replacements might also help address nutritional deficiencies caused by GLP-1 RAs